1.
Breton G, Froissart M, Janus N, Launay-Vacher V, Berr C, Tzourio C, et al. Inappropriate
drug use and mortality in community-dwelling elderly with impaired kidney function--the
Three-City population-based study. Nephrol Dial Transplant. 2011 Sep 1;26(9):2852–9.
2.
Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related Problems
in CKD. Adv Chronic Kidney Dis. 2010 Sep;17(5):404–12.
3.
Qato D, Caleb G, Johnson M, Schumm P, Tessler Lindau S. Use of Prescription and Over-the-counter
Medications and Dietary Supplements Among Older Adults in the United States. JAMA.
2008 Dec 24;300(24):2867.
4.
Hsu KL, Fink JC, Ginsberg JS, Yoffe M, Zhan M, Fink W, et al. Self-reported Medication
Adherence and Adverse Patient Safety Events in CKD. Am J Kidney Dis. 2015 Oct;66(4):621–9.
5.
Wong NA, Jones HW. An analysis of discharge drug prescribing amongst elderly patients
with renal impairment. Postgrad Med J. 1998;74(873):420–2.
6.
Chang F, O’Hare AM, Miao Y, Steinman MA. Use of Renally Inappropriate Medications
in Older Veterans: A National Study. J Am Geriatr Soc. 2015 Nov;63(11):2290–7.
7.
Bongue B, Laroche ML, Gutton S, Colvez A, Guéguen R, Moulin JJ, et al. Potentially
inappropriate drug prescription in the elderly in France: a population-based study
from the French National Insurance Healthcare system. Eur J Clin Pharmacol. 2011 Dec;67(12):1291–9.
8.
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American
Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication
Use in Older Adults. J Am Geriatr Soc. 2015 Nov;63(11):2227–46.
9.
Laroche M, Charmes J, Nouaille Y, Fourrier A, Merle L. Impact of hospitalisation in
an acute medical geriatric unit on potentially inappropriate medication use. Drugs
Aging. 2006;23(1):49–59.
10.
Jones SA, Bhandari S. The prevalence of potentially inappropriate medication prescribing
in elderly patients with chronic kidney disease. Postgrad Med J. 2013 May;89(1051):247–50.
11.
Fick DM, Waller JL, Maclean JR. Potentially inappropriate medication use in a Medicare
managed care population: association with higher costs and utilization. J Manag Care
Pharm. 2001;7(5):407–13.
12.
Moranne O, Couchoud C, Vigneau C, PSPA Study Investigators. Characteristics and Treatment
Course of Patients Older Than 75 Years, Reaching End-Stage Renal Failure in France.
The PSPA Study. J Gerontol A Biol Sci Med Sci. 2012 Dec 1;67(12):1394–9.
14.
Vidal dictionaries. 91th ed. Paris: Vidal SA; 2015.
15.
Information Conseil Adaptation Rénale ICAR. http://www.sitegpr .com/ last accessed
in june 2017.
18.
Laroche M-L, Bouthier F, Merle L, Charmes J-P. Potentially inappropriate medications
in the elderly: Interest of a list adapted to the French medical practice. Rev Med
Interne. 2009 Jul;30(7):592–601.
19.
Gargiulo R, Suhail F, Lerma EV. Cardiovascular disease and chronic kidney disease.
Dis Mon. 2015 Sep;61(9):403–13.
20.
Laroche M-L, Charmes J-P, Nouaille Y, Picard N, Merle L. Is inappropriate medication
use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007
Feb;63(2):177–86.
21.
Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. 2013 Practice
guidelines for the management of arterial hypertension of the European Society of
Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force
for the Management of Arterial Hypertension. J Hypertens. 2013 Oct;31(10):1925–38.
22.
Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities
for improving the care of patients with chronic renal insufficiency: current practice
patterns. J Am Soc Nephrol. 2001;12(8):1713–1720.
23.
Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication
use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol
Dial Transplant. 2005 Jun 1;20(6):1110–5.
24.
Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and
the use of cardioprotective medications in patients with chronic renal insufficiency.
Am J Kidney Dis. 2001 Mar;37(3):484–9.
25.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The
Task Force for the diagnosis and treatment of acute and chronic heart failure of the
European Society of Cardiology (ESC). Developed with the spec. Eur J Heart Fail. 2016
Aug;18(8):891–975.
26.
Ruilope LM. Chronic kidney disease: Blood pressure control in CKD--still a matter
of debate. Nat Rev Nephrol. 2013;9(10):572–3.
27.
Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of
the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol
Dial Transplant. 2010 Dec 1;25(12):3977–82.
28.
Moranne O, Froissart M, Rossert J, Gauci C, Boffa J-J, Haymann JP, et al. Timing of
Onset of CKD-Related Metabolic Complications. J Am Soc Nephrol. 2009 Jan 1;20(1):164–71.
29.
Ito T, Jensen RT. Association of Long-Term Proton Pump Inhibitor Therapy with Bone
Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium.
Curr Gastroenterol Rep. 2010 Dec;12(6):448–57.
30.
Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia
in Type 2 Diabetic Nephropathy: A novel predictor of end-stage renal disease. Diabetes
Care. 2012 Jul 1;35(7):1591–7.
31.
Aparicio M, Dratwa M, El Esper N, Fillastre JP, Levaltier B, Lins R, et al. Pharmacokinetics
of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.
Am J Cardiol. 1994;43–50.
32.
Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate
of hepatic organic anion transporter OATP-C. Atheroscler. 90(supp2):174.
33.
Fellström B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al. Effect
of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from
the AURORA Study. Kidney Blood Press Res. 2007;30(5):314–22.
34.
Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, et al. Population
pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia.
Curr Med Res Opin. 2008;24(9):2575–85.
35.
Marbury TC, Blum RA, Rauch C, Pinquier J-L. Pharmacokinetics and Safety of a Single
Oral Dose of Once-Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal
Impairment. J Clin Pharmacol. 2002 Dec;42(12):1311–7.
37.
Gallagher PF, Barry PJ, Ryan C, Hartigan I, O’Mahony D. Inappropriate prescribing
in an acutely ill population of elderly patients as determined by Beers’ Criteria.
Age Ageing. 2007 Oct 11;37(1):96–101.
38.
Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular
protection in chronic kidney disease. Nat Rev Cardiol. 2016 Apr 7;13(10):603–8.
39.
De Rhodes KH. The Dangers of Ignoring the Beers Criteria-The Prescribing Cascade.
JAMA Intern Med. 2019 May 13;
40.
Leguelinel-Blache G, Dubois F, Bouvet S, Roux-Marson C, Arnaud F, Castelli C, et al.
Improving Patientʼs Primary Medication Adherence: The Value of Pharmaceutical Counseling.
Medicine (Baltimore). 2015 Oct;94(41):e1805.
41.
McIntyre C, McQuillan R, Bell C, Battistella M. Targeted Deprescribing in an Outpatient
Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy. Am J Kidney
Dis. 2017;S0272-6386(17):30582–6.
42.
Triantafylidis LK, Hawley CE, Perry LP, Paik JM. The Role of Deprescribing in Older
Adults with Chronic Kidney Disease. Drugs Aging. 2018;35(11):973–84.